Skip to main
DCTH

Delcath Systems (DCTH) Stock Forecast & Price Target

Delcath Systems (DCTH) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Delcath Systems is poised for strong growth driven by its selective approach to site quality, which could support volume growth per site and improve its financials. The company reported strong financials for the second quarter of 2026, with an increase in revenue and net income, and raised its 2026 revenue guidance based on the strength of its sales performance, adding two more centers to its active treatment centers. With a focus on key drivers of growth, including high-volume academic institutions and recurring referrals, as well as improved commercial execution, Delcath Systems is on track for continued success in the future.

Bears say

Delcath Systems is reporting better than expected gross margins due to operational efficiencies and has adjusted their R&D and SG&A expenses for the remainder of 2026 as a result. The company has 13 active screening sites for its Phase 2 randomized controlled trial (RCT) in liver-dominant metastatic colorectal cancer, with expected interim results in late 2027, and 6 active screening sites for its RCT in liver-dominant metastatic breast cancer. The first patients in the breast cancer trial have recently been dosed.

Delcath Systems (DCTH) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Delcath Systems and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Delcath Systems (DCTH) Forecast

Analysts have given Delcath Systems (DCTH) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Delcath Systems (DCTH) has a Strong Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Delcath Systems (DCTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.